Literature DB >> 29484157

Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review.

T S Chew1, J C Mansfield1.   

Abstract

Crohn's disease and ulcerative colitis are chronic inflammatory disorders affecting the gastrointestinal tract. Faecal calprotectin is a protein complex of the S-100 family of calcium-binding proteins present in inflammatory cells that can be measured in stool samples, which act as a biomarker for bowel inflammation. Elevated faecal calprotectin has been shown to reflect the presence of ongoing mucosal inflammation, which improves with mucosal healing. The aim of this review was to evaluate the available evidence on the ability of faecal calprotectin to predict a relapse in inflammatory bowel disease. Multiple retrospective studies have shown that patients who relapse have significantly higher levels of calprotectin in their stool compared with non-relapsers, especially in ulcerative colitis. Elevated faecal calprotectin postoperatively in Crohn's disease was also shown to be indicative of a relapse. However, the association of a raised faecal calprotectin and relapse is not universal and may be explained by the different patterns of mucosal inflammatory activity that exist. In conclusion, we put forward our hypothesis that changes such as a rise in faecal calprotectin levels may be more predictive of a relapse than absolute values.

Entities:  

Keywords:  CROHN'S DISEASE; INFLAMMATORY BOWEL DISEASE; ULCERATIVE COLITIS

Year:  2016        PMID: 29484157      PMCID: PMC5824761          DOI: 10.1136/flgastro-2016-100686

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  32 in total

1.  Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue - Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up.

Authors:  Quentin Delefortrie; Patricia Schatt; Alexandre Grimmelprez; Patrick Gohy; Didier Deltour; Geneviève Collard; Patrick Vankerkhoven
Journal:  Clin Biochem       Date:  2015-10-24       Impact factor: 3.281

2.  The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound.

Authors:  A Orlando; I Modesto; F Castiglione; L Scala; D Scimeca; A Rispo; S Teresi; F Mocciaro; V Criscuoli; C Marrone; P Platania; T De Falco; S Maisano; N Nicoli; M Cottone
Journal:  Eur Rev Med Pharmacol Sci       Date:  2006 Jan-Feb       Impact factor: 3.507

3.  Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.

Authors:  Lamia Kallel; Imen Ayadi; Samira Matri; Monia Fekih; Nadia Ben Mahmoud; Moncef Feki; Sami Karoui; Bechir Zouari; Jalel Boubaker; Naziha Kaabachi; Azza Filali
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-03       Impact factor: 2.566

4.  A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease.

Authors:  Graham D Naismith; Lyn A Smith; Sarah J E Barry; Joanna I Munro; Susan Laird; Karen Rankin; Allan J Morris; Jack W Winter; Daniel R Gaya
Journal:  J Crohns Colitis       Date:  2014-02-22       Impact factor: 9.071

5.  Faecal calprotectin in children with clinically quiescent inflammatory bowel disease.

Authors:  Taina Sipponen; Kaija-Leena Kolho
Journal:  Scand J Gastroenterol       Date:  2010-08       Impact factor: 2.423

6.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

Authors:  J A Tibble; G Sigthorsson; S Bridger; M K Fagerhol; I Bjarnason
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

7.  Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.

Authors:  Erik Mooiweer; Mirjam Severs; Marguerite E I Schipper; Herma H Fidder; Peter D Siersema; Robert J F Laheij; Bas Oldenburg
Journal:  J Crohns Colitis       Date:  2014-11-26       Impact factor: 9.071

8.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

9.  Clinical application of faecal calprotectin in ulcerative colitis patients.

Authors:  Eleonora Scaioli; Michele Scagliarini; Carla Cardamone; Elisa Liverani; Giampaolo Ugolini; Davide Festi; Franco Bazzoli; Andrea Belluzzi
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-12       Impact factor: 2.566

10.  Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease.

Authors:  C A Lamb; J C Mansfield
Journal:  Frontline Gastroenterol       Date:  2010-11-03
View more
  4 in total

1.  Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.

Authors:  Fernando Magro; Susana Lopes; Marco Silva; Rosa Coelho; Francisco Portela; Diogo Branquinho; Luís Correia; Samuel Fernandes; Marília Cravo; Paulo Caldeira; Helena Tavares de Sousa; Marta Patita; Paula Lago; Jaime Ramos; Joana Afonso; Isabel Redondo; Patrícia Machado; George Philip; Joanne Lopes; Fátima Carneiro
Journal:  Therap Adv Gastroenterol       Date:  2019-08-30       Impact factor: 4.409

2.  Novel Models for Chronic Intestinal Inflammation in Chickens: Intestinal Inflammation Pattern and Biomarkers.

Authors:  Gabriela C Dal Pont; Bruna L Belote; Annah Lee; Cristiano Bortoluzzi; Cinthia Eyng; Milena Sevastiyanova; Alireza Khadem; Elizabeth Santin; Yuhua Z Farnell; Christos Gougoulias; Michael H Kogut
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 3.  Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases.

Authors:  Alicja Derkacz; Pawel Olczyk; Katarzyna Komosinska-Vassev
Journal:  Dis Markers       Date:  2018-06-11       Impact factor: 3.434

4.  Point-of-care gastrointestinal ultrasound in inflammatory bowel disease: An accurate alternative for disease monitoring.

Authors:  Dharshan Sathananthan; Arvind Rajagopalan; Lucinda Van De Ven; Serena Martin; James Fon; Samuel Costello; Robert V Bryant
Journal:  JGH Open       Date:  2019-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.